← Leaderboards
Charles Andrew Stewart
Cartesian Therapeutics, Inc.
$5,769,845
Attributed
$5,769,845
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,769,845 · 4
By mechanism
R44$5,470,803 · 3
R43$299,042 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Toxic Effect”
- Matthew Johnson · Duke University$56,071,536
- John Damon Chodera · Sloan-Kettering Inst Can Research$25,853,758
- Kristin Aillon · Midwest Research Institute$24,228,962
- Bronwen Shaw · Medical College Of Wisconsin$19,182,557
- Xinhua Li · Nano Terra, Inc.$17,491,533
- Thomas Denny · Duke University$16,626,143
Research focus
Toxic EffectSmall Business Innovation Research GrantSafetyClinical TrialsCell TherapyMessenger RnaInfusion ProceduresDoseDesignProductionInflammatory ResponseCytokineMalignant NeoplasmsCytokine Release SyndromeCell MaturationDose-LimitingMaximum Tolerated DoseB-LymphocytesClinical DevelopmentBloodCyclic GmpClinical ResearchImmunophenotypingAntigens
Grant awards (6)
Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD)$1,496,118
R44 · FY2025 · NS · contact PI
Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome$999,491
R44 · FY2022 · HL · contact PI
Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome$998,742
R44 · FY2021 · HL · contact PI
Phase 1/2 Clinical Study of Humanized Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma (MM)$988,226
R44 · FY2021 · CA · contact PI
Phase 1/2 Clinical Study of Humanized Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma (MM)$988,226
R44 · FY2020 · CA · contact PI
Transient anti-BCMA CAR T-cells for Treatment of Multiple Myeloma$299,042
R43 · FY2018 · CA · contact PI